butyric acid has been researched along with Bowel Diseases, Inflammatory in 13 studies
Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.
butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.
butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients aged 6-18 years with colonic Crohn's disease or ulcerative colitis, who received standard therapy depending on the disease's severity, were randomized to receive 150 mg sodium butyrate twice a day (group A) or placebo (group B)." | 3.11 | Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial. ( Banasiuk, M; Banaszkiewicz, A; Borys-Iwanicka, A; Pietrzak, A; Pytrus, T; Szczepanik, M; Walkowiak, J, 2022) |
| "We induced ulcerative colitis (UC) in mice utilizing dextran sodium sulfate (DSS) in the drinking water for 7 days." | 1.91 | Sodium Butyrate Protects Against Intestinal Oxidative Damage and Neuroinflammation in the Prefrontal Cortex of Ulcerative Colitis Mice Model. ( De Oliveira, J; do Nascimento, ND; Fröhlich, NT; Gelain, DP; Gomes, HM; Kessler, F; Martins, A; Moreira, JCF; Paz, AH; Possa, L; Rodrigues, MS; Santos, L; Silveira, AK; Sirena, D, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 8 (61.54) | 2.80 |
| Authors | Studies |
|---|---|
| Pietrzak, A | 1 |
| Banasiuk, M | 1 |
| Szczepanik, M | 1 |
| Borys-Iwanicka, A | 1 |
| Pytrus, T | 1 |
| Walkowiak, J | 2 |
| Banaszkiewicz, A | 1 |
| Xia, X | 2 |
| Lin, H | 2 |
| Luo, F | 2 |
| Wu, X | 2 |
| Zhu, L | 2 |
| Chen, S | 2 |
| Luo, H | 2 |
| Ye, F | 2 |
| Peng, X | 2 |
| Zhang, Y | 2 |
| Yang, G | 2 |
| Lin, Q | 2 |
| Ikeda, Y | 1 |
| Matsuda, S | 1 |
| Silveira, AK | 1 |
| Gomes, HM | 1 |
| Fröhlich, NT | 1 |
| Possa, L | 1 |
| Santos, L | 1 |
| Kessler, F | 1 |
| Martins, A | 1 |
| Rodrigues, MS | 1 |
| De Oliveira, J | 1 |
| do Nascimento, ND | 1 |
| Sirena, D | 1 |
| Paz, AH | 1 |
| Gelain, DP | 1 |
| Moreira, JCF | 1 |
| Kaden-Volynets, V | 1 |
| Günther, C | 1 |
| Zimmermann, J | 1 |
| Beisner, J | 1 |
| Becker, C | 1 |
| Bischoff, SC | 1 |
| Facchin, S | 2 |
| Vitulo, N | 1 |
| Calgaro, M | 1 |
| Buda, A | 2 |
| Romualdi, C | 1 |
| Pohl, D | 1 |
| Perini, B | 1 |
| Lorenzon, G | 1 |
| Marinelli, C | 1 |
| D'Incà, R | 1 |
| Sturniolo, GC | 1 |
| Savarino, EV | 1 |
| Sitkin, S | 1 |
| Vakhitov, T | 1 |
| Pokrotnieks, J | 1 |
| Savarino, E | 1 |
| Jamka, M | 1 |
| Kokot, M | 1 |
| Kaczmarek, N | 1 |
| Bermagambetova, S | 1 |
| Nowak, JK | 1 |
| Van Immerseel, F | 1 |
| Ducatelle, R | 1 |
| De Vos, M | 1 |
| Boon, N | 1 |
| Van De Wiele, T | 1 |
| Verbeke, K | 1 |
| Rutgeerts, P | 1 |
| Sas, B | 1 |
| Louis, P | 1 |
| Flint, HJ | 1 |
| Sossai, P | 1 |
| Takaishi, H | 1 |
| Matsuki, T | 1 |
| Nakazawa, A | 1 |
| Takada, T | 1 |
| Kado, S | 1 |
| Asahara, T | 1 |
| Kamada, N | 1 |
| Sakuraba, A | 1 |
| Yajima, T | 1 |
| Higuchi, H | 1 |
| Inoue, N | 1 |
| Ogata, H | 1 |
| Iwao, Y | 1 |
| Nomoto, K | 1 |
| Tanaka, R | 1 |
| Hibi, T | 1 |
| D'Argenio, G | 1 |
| Mazzacca, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Inflammation and Intestinal Microbiota Modulation in Inflammatory Bowel Diseases[NCT04879914] | 160 participants (Actual) | Interventional | 2020-06-01 | Completed | |||
| A Randomized Controlled Trial to Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain in Overweight But Generally Healthy Adults Over the Winter Holiday Period[NCT03372109] | 23 participants (Actual) | Interventional | 2017-11-14 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for butyric acid and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
The Effect of Sodium Butyrate Enemas Compared with Placebo on Disease Activity, Endoscopic Scores, and Histological and Inflammatory Parameters in Inflammatory Bowel Diseases: A Systematic Review of Randomised Controlled Trials.
Topics: Butyric Acid; Colitis, Ulcerative; Enema; Humans; Inflammatory Bowel Diseases; Randomized Controlled | 2021 |
Butyric acid: what is the future for this old substance?
Topics: beta-Thalassemia; Butyric Acid; Humans; Inflammatory Bowel Diseases; Intestinal Mucosa; Intestines; | 2012 |
Short-chain fatty acid in the human colon. Relation to inflammatory bowel diseases and colon cancer.
Topics: Butyric Acid; Colon; Colonic Neoplasms; Dietary Fiber; Fatty Acids; Humans; Inflammatory Bowel Disea | 1999 |
2 trials available for butyric acid and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial.
Topics: Adolescent; Butyric Acid; Child; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Dise | 2022 |
Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease.
Topics: Administration, Oral; Adult; Aged; Butyric Acid; Capsules; Double-Blind Method; Female; Gastrointest | 2020 |
8 other studies available for butyric acid and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Oryzanol Ameliorates DSS-Stimulated Gut Barrier Damage via Targeting the Gut Microbiota Accompanied by the TLR4/NF-κB/NLRP3 Cascade Response In Vivo.
Topics: Animals; Butyric Acid; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Gastrointestinal Mic | 2022 |
Oryzanol Ameliorates DSS-Stimulated Gut Barrier Damage via Targeting the Gut Microbiota Accompanied by the TLR4/NF-κB/NLRP3 Cascade Response In Vivo.
Topics: Animals; Butyric Acid; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Gastrointestinal Mic | 2022 |
Oryzanol Ameliorates DSS-Stimulated Gut Barrier Damage via Targeting the Gut Microbiota Accompanied by the TLR4/NF-κB/NLRP3 Cascade Response In Vivo.
Topics: Animals; Butyric Acid; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Gastrointestinal Mic | 2022 |
Oryzanol Ameliorates DSS-Stimulated Gut Barrier Damage via Targeting the Gut Microbiota Accompanied by the TLR4/NF-κB/NLRP3 Cascade Response In Vivo.
Topics: Animals; Butyric Acid; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Gastrointestinal Mic | 2022 |
Gut Protective Effect from D-Methionine or Butyric Acid against DSS and Carrageenan-Induced Ulcerative Colitis.
Topics: Animals; Butyric Acid; Carrageenan; Colitis; Colitis, Ulcerative; Dextran Sulfate; Disease Models, A | 2023 |
Sodium Butyrate Protects Against Intestinal Oxidative Damage and Neuroinflammation in the Prefrontal Cortex of Ulcerative Colitis Mice Model.
Topics: Animals; Butyric Acid; Claudin-5; Colitis, Ulcerative; Disease Models, Animal; Inflammation; Inflamm | 2023 |
Deletion of the Casp8 gene in mice results in ileocolitis, gut barrier dysfunction, and malassimilation, which can be partially attenuated by inulin or sodium butyrate.
Topics: Animals; Body Weight; Butyric Acid; Caspase 8; Crohn Disease; Diet, Western; Dietary Supplements; Fe | 2019 |
Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes.
Topics: Butyrates; Butyric Acid; Colitis; Gastrointestinal Microbiome; Humans; Inflammatory Bowel Diseases; | 2021 |
Reply Letter to "Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes".
Topics: Butyric Acid; Colitis; Gastrointestinal Microbiome; Humans; Inflammatory Bowel Diseases; Microbiota | 2021 |
Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease.
Topics: Bacteria, Anaerobic; Butyric Acid; Fermentation; Humans; Inflammatory Bowel Diseases; Probiotics | 2010 |
Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease.
Topics: Actinobacteria; Bacteria; Bacteroides; Bifidobacterium; Biodiversity; Butyric Acid; Clostridium; Col | 2008 |